Ipsen SA

118,60

10-января-25 04:15:35

15 мин. задержка

Акции

-0,35

-0,29%

Сегодняшний диапазон

118,50 - 118,90

ISIN

FR0010259150

Источник

Cboe

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

25 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

25 июл 2024 00:58:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

23 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

16 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

11 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

09 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Half-year statement of IPSEN liquidity agreement - 2024 06 30

08 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

02 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

02 июл 2024 01:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

25 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

18 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

11 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

10 июн 2024 16:54:20 Источник Nasdaq GlobeNewswire
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform

07 июн 2024 01:00:00 Источник Nasdaq GlobeNewswire
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 июн 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

06 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

05 июн 2024 02:00:00 Источник Nasdaq GlobeNewswire
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan

03 июн 2024 01:00:00 Источник Nasdaq GlobeNewswire
Ipsen announces the launch of an employee shareholding plan

30 май 2024 12:15:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.